secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2024-05-31T23:59:59+00:00
Accession:  0001493152-24-022193
Event type: other
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte approves salary increases for CEO, interim CFO, and CSO effective May 20, 2024
--------------------------------------------------------------------------------

- CEO Joshua Riggs' base salary increased from $360,000 to $400,000.
- Interim CFO/Principal Accounting Officer James Liu's salary raised from $200,000 to $207,000.
- Chief Science Officer Ekkehard Schütz's salary rose from $351,525 to $378,025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224022193/0001493152-24-022193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224022193/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-022193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer